Skip to main content
SpringerLink
Log in

Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome

  • Editorial Comment
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

When and why does the medical management of the gastric secretory activity of patients with the Zollinger-Ellison syndrome fail? (Editor's note). In the November issue of Digestive Diseases and Sciences, a paper by Ziemniak and associates discussed the reasons for failure of cimetidine in the treatment of Zollinger-Ellison syndrome. The editors have invited Dr. R.T. Jensen of the Intramural Program in Digestive Diseases at the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases to comment on this important problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Richardson CT, Walsh JH: The value of histamine H2-receptor antagonist in the management of patients with Zollinger-Ellison syndrome. N Engl J Med 294:133–135, 1976

    Google Scholar 

  2. McCarthy DM, Olinger EJ, May RJ, Long BW, Gardner JD: H2-histamine receptor blocking agents in the Zollinger-Ellison syndrome. Ann Intern Med 87:668–675, 1977

    Google Scholar 

  3. Bonfils S, Mignon M, Jian R, Kloeti G: Biological studies during long-term cimetidine administration in Zollinger-Ellison syndrome.In Cimetidine: Proceedings of the Second International Symposium on Histamine H2-Receptor Antagonists. WL Burland, MA Simkins (ed). Amsterdam, Excerpta Medica, 1977, pp 311–321

    Google Scholar 

  4. McCarthy DM: Report on the United States experience with cimetidine in the Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 74:453–458, 1978

    Google Scholar 

  5. McCarthy DM: The place of surgery in the Zollinger-Ellison syndrome. N Engl J Med 302:1344–1347, 1980

    Google Scholar 

  6. Deveney CW, Stein S, Way LW: Cimetidine in the treatment of Zollinger-Ellison syndrome. Am J Surg 146:116–123, 1983

    Google Scholar 

  7. Stabile BE, Ippoliti AF, Walsh JH, Passaro E Jr: Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome. Am J Surg 145:17–23, 1983

    Google Scholar 

  8. Bonfils S, Mignon M, Gratton J: Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome. World J Surg 3:597–604, 1979

    Google Scholar 

  9. Mignon M, Vallot T, Hervoir P, Benfredj P, Bonfils S: Ranitidine versus cimetidine in the management of Zollinger-Ellison syndrome.In Ranitidine: Proceedings of an International Symposium Held in the Context of the Seventh World Congress of Gastroenterology. AJ Riley, RP Salmon (eds). Amsterdam, Excerpta Medica, 1982, pp 169–177

    Google Scholar 

  10. Lamers CBH, Festen HPM, von Tongeren JHM: Long-term treatment with histamine H2-receptor antagonists in Zollinger-Ellison syndrome. Am J Gastroenterol 70:286–291, 1978

    Google Scholar 

  11. Rune SJ, Larsen N-E, Stadil F, Worning H: Development of resistance to cimetidine in a patient with Zollinger-Ellison syndrome. Gastroenterology 90:1265, 1981

    Google Scholar 

  12. Allende HD, Bissonnette BM, Raufman J-P, Pandol SJ, Collen MJ, McCarthy DM, Gardner JD, Jensen RT: Progressive increase in drug requirement in the long-term medical management of patients with Zollinger-Ellison syndrome (ZES). Gastroenterology 82:1064, 1982

    Google Scholar 

  13. Creutzfeldt W: Discussion.In Cimetidine. W. Creutzfeldt (ed). Amsterdam, Excerpta Medica, 1977, p 149

    Google Scholar 

  14. Deveney CW, Deveney KS, Way LW: The Zollinger-Ellison syndrome—23 years later. Ann Surg 188:384–393, 1978

    Google Scholar 

  15. Malagelada J-R, Edis AJ, Adson MA, van Heerden JA, Go VLW: Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84:1524–1532, 1983

    Google Scholar 

  16. Jensen RT, Gardner JD, Raufman J-P, Pandol SJ, Doppman JL, Collen MJ: Zollinger-Ellison syndrome. NIH combined clinical staff conference (RT Jensen, moderator) Ann Intern Med 98:59–75, 1983

    Google Scholar 

  17. Stadil F, Stage JG: Cimetidine and the Zollinger-Ellison (Z-E) syndrome.In The Westminster Hospital Symposium. C Wastell, P Lance (eds) London, Churchill Livingstone, 1978, pp 91–104

    Google Scholar 

  18. Gugler R, Fuchs G, Dieckmann M, Somogyi AA: Cimetidine. Plasma concentration-response relationships. Clin Pharmacol Ther 29:744–748, 1981

    Google Scholar 

  19. Vallot T, Mignon M, Mazur R, Bonfils S: Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring. Dig Dis Sci 28:577–584, 1983

    Google Scholar 

  20. Summerskill WH: Malabsorption and jejunal ulceration due to gastric hypersecretion with pancreatic islet cell hyperplasia. Lancet 1:120–123, 1959

    Google Scholar 

  21. Shimoda SS, Sanders DR, Rubin CE: The Zollinger-Ellison syndrome with steatorrhea: II. The mechanisms of fat and vitamin B12 malabsorption. Gastroenterology 55:705–723, 1968

    Google Scholar 

  22. Somogyi A, Gugler R: Drug interactions with cimetidine. Clin Pharmacokinet 7:23–41, 1981

    Google Scholar 

  23. Raufman J-P, Collen MJ, Howard JM, McArthur KE, Gardner JD, Jensen RT: Decreased parietal cell responsiveness to cimetidine in some patients with Zollinger-Ellison syndrome (ZES). Gastroenterology 84:1281, 1983

    Google Scholar 

  24. Raufman J-P, Collins SM, Pandol SJ, Korman LK, Collen MJ, Cornelius MJ, Feld MK, McCarthy DM, Gardner JD, Jensen RT: Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84:108–113, 1983

    Google Scholar 

  25. Zollinger RM, Ellison EH: Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709–723, 1955

    Google Scholar 

  26. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS: Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer diseases and other allied diseases. Drugs 24:267–303, 1982

    Google Scholar 

  27. McCallum RW, Kuljian B, Chremos AN, Typy-Visich MA, Huber PB: Prolonged gastric antisecretory effect of a novel H2-receptor inhibitor, MK-208. Gastroenterology 84:1245, 1983

    Google Scholar 

  28. Baron JH, Londong W (eds): Advances in basic and clinical pharmacology of pirenzepine. Scand J Gastroenterol 15 (Suppl 66):1–114, 1980

  29. Walt RP, Gomes MFA, Wood EC, Logan LH, Pounder RE: Effect of daily oral omeprazole on 24-hour intragastric acidity. Br Med J 287:12–14, 1983

    Google Scholar 

  30. Collen MJ, Howard JM, McArthur KE, Raufman JP, Cornelius MJ, Ciarleglio CA, Gardner JD, Jensen RT: Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 100:52–58, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Diseases Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, 20205, Bethesda, Maryland

    R. T. Jensen

Authors
  1. R. T. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jensen, R.T. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Digest Dis Sci 29, 363–366 (1984). https://doi.org/10.1007/BF01318525

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01318525

Search

Navigation